EQNR323.30-4.60%
MOWI187.80-1.57%
YARA432.10+0.30%
TEL144.40+1.69%
Brent$74.12-2.61%
USD/NOK9,8084−0,34 %
EUR/NOK11,2140−0,18 %
LIVE · 16:42 UTC
GENE56

GENE.DH

IT Services & ConsultingLatest Reported

GENE.DH's capital structure is characterized by a high debt-to-equity ratio of 1.43, indicating a significant reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.63, suggesting limited short-term liquidity to cover immediate liabilities. Despite a cash and equivalents balance of BDT 78.99 million, the company's long-term debt of BDT 3.73 billion creates a net cash negative position, raising concerns about long-term solvency. In terms of profitability, GENE.DH's return on equity (ROE) of 9.96% and return on assets (ROA) of 3.95% are below the industry median for IT Services & Consulting, indicating suboptimal capital efficiency and asset utilization. The company's operating margin of 16.6% (calculated from operating income of BDT 317.64 million on revenue of BDT 1.91 billion) is also below the industry average, suggesting room for improvement in cost management and pricing power. The company's revenue is concentrated in a single business segment, IT Services, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic downturns and regulatory shifts. The absence of segment-specific revenue breakdowns in the financial data limits the ability to assess the performance of individual business lines. GENE.DH's growth trajectory is constrained by negative free cash flow of BDT -143.54 million and capital expenditures of BDT -862.21 million, indicating that the company is investing heavily in infrastructure but not generating sufficient cash to fund these investments. The outlook for the current fiscal year shows a modest revenue increase, but the next fiscal year is expected to see a decline, reflecting potential market saturation or operational inefficiencies. The risk assessment highlights liquidity as a medium concern, with the company's net cash position being negative after accounting for total debt. The dilution risk is assessed as low, with no significant dilution events reported in the recent financial data. However, the company's reliance on debt financing and negative free cash flow could lead to future dilution if additional capital is required. Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's focus remains on expanding its IT services portfolio and improving operational efficiency. No significant regulatory changes or geopolitical events are currently impacting the company's operations.

30-day price · GENE(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyGENE.DH
TickerGENE.DH
SectorTechnology
BusinessSoftware & IT Services
Industry groupSoftware & IT Services
IndustryIT Services & Consulting
AI analysis

Business. GENE.DH provides IT services and consulting solutions, generating revenue primarily through service contracts and project-based engagements.

Classification. GENE.DH is classified under the Technology sector, specifically in the Software & IT Services business sector, with a confidence level of 0.92.

GENE.DH's capital structure is characterized by a high debt-to-equity ratio of 1.43, indicating a significant reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.63, suggesting limited short-term liquidity to cover immediate liabilities. Despite a cash and equivalents balance of BDT 78.99 million, the company's long-term debt of BDT 3.73 billion creates a net cash negative position, raising concerns about long-term solvency. In terms of profitability, GENE.DH's return on equity (ROE) of 9.96% and return on assets (ROA) of 3.95% are below the industry median for IT Services & Consulting, indicating suboptimal capital efficiency and asset utilization. The company's operating margin of 16.6% (calculated from operating income of BDT 317.64 million on revenue of BDT 1.91 billion) is also below the industry average, suggesting room for improvement in cost management and pricing power. The company's revenue is concentrated in a single business segment, IT Services, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic downturns and regulatory shifts. The absence of segment-specific revenue breakdowns in the financial data limits the ability to assess the performance of individual business lines. GENE.DH's growth trajectory is constrained by negative free cash flow of BDT -143.54 million and capital expenditures of BDT -862.21 million, indicating that the company is investing heavily in infrastructure but not generating sufficient cash to fund these investments. The outlook for the current fiscal year shows a modest revenue increase, but the next fiscal year is expected to see a decline, reflecting potential market saturation or operational inefficiencies. The risk assessment highlights liquidity as a medium concern, with the company's net cash position being negative after accounting for total debt. The dilution risk is assessed as low, with no significant dilution events reported in the recent financial data. However, the company's reliance on debt financing and negative free cash flow could lead to future dilution if additional capital is required. Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's focus remains on expanding its IT services portfolio and improving operational efficiency. No significant regulatory changes or geopolitical events are currently impacting the company's operations.
Key takeaways
  • GENE.DH has a high debt-to-equity ratio of 1.43, indicating a heavy reliance on debt financing.
  • The company's ROE of 9.96% and ROA of 3.95% are below the industry median, suggesting suboptimal capital efficiency.
  • GENE.DH's liquidity position is medium, with a current ratio of 0.63 and a net cash negative position.
  • The company's free cash flow is negative, and capital expenditures are high, indicating significant investment in infrastructure.
  • Revenue is concentrated in a single business segment, increasing exposure to regional economic downturns.
  • The company's growth trajectory is constrained, with a modest revenue increase expected in the current fiscal year and a decline in the next fiscal year.
Financial snapshot
PeriodLatest reported
CurrencyBDT
Revenue$1.91B
Gross profit$860.6M
Operating income$317.6M
Net income$260.8M
R&D
SG&A
D&A
SBC
Operating cash flow$827.5M
CapEx-$862.2M
Free cash flow-$143.5M
Total assets$6.61B
Total liabilities$3.99B
Total equity$2.62B
Cash & equivalents$79.0M
Long-term debt$3.73B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.62B
Net cash-$3.65B
Current ratio0.6
Debt/Equity1.4
ROA4.0%
ROE10.0%
Cash conversion3.2%
CapEx/Revenue-45.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: IT Services · cohort 787 companies
MetricGENEActivity
Op margin16.6%4.8% medp25 -4.8% · p75 10.9%top quartile
Net margin13.6%3.7% medp25 -3.9% · p75 9.0%top quartile
Gross margin45.0%33.4% medp25 20.5% · p75 59.4%above median
R&D / revenue16.8% medp25 15.6% · p75 20.2%
CapEx / revenue-45.1%-2.2% medp25 -6.8% · p75 -0.6%bottom quartile
Debt / equity143.0%13.0% medp25 1.9% · p75 44.3%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 23:39 UTC#663ef153
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 00:33 UTCJob: f21257cc